XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Nature of Business, Merger and Basis of Presentation (Details) |  | 3 Months Ended |
--- | --- | --- | ---
Jan. 04, 2018 $ / shares shares | Mar. 31, 2018 Program Platform $ / shares | Dec. 31, 2017 $ / shares
Business Acquisition [Line Items] |  |  |
Number of programs currently undergoing clinical testing targeting Fanconi Anemia | Program |  | 2 |
Number of additional programs in preclinical stages targeting other rare genetic diseases | Program |  | 3 |
Estimated period to file an investigational new drug application |  | 12 months |
Number of technology platforms designed in collaboration with academic and industry partners | Platform |  | 2 |
Common stock, par value (in dollars per share) | $ / shares |  | $ 0.01 | $ 0.01
Common Stock [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Ownership percentage held by parent on fully diluted basis | 81.357% |  |
Inotek [Member] | Common Stock [Member] |  |  |
Business Acquisition [Line Items] |  |  |
Number of shares received pursuant to merger agreement (in shares) | shares | 76.185 |  |
Common stock, par value (in dollars per share) | $ / shares | $ 0.01 |  |
Non-controlling interest, ownership percentage on fully diluted basis | 18.643% |  |

X
- Definition The estimated period to file an investigational new drug application in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rckt_EstimatedPeriodToFileAnInvestigationalNewDrugApplication
Namespace Prefix: | rckt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of additional programs currently under preclinical stages targeting other rare genetic diseases. + References No definition available. + Details
Name: | rckt_NumberOfAdditionalProgramsUnderPreclinicalStagesTargetingOtherRareGeneticDiseases
Namespace Prefix: | rckt_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of program currently undergoing clinical testing targeting Fanconi Anemia. + References No definition available. + Details
Name: | rckt_NumberOfProgramsCurrentlyUndergoingClinicalTestingTargetingFanconiAnemia
Namespace Prefix: | rckt_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The leading technology platforms LVV and AAV are each being designed in collaboration with leading academic and industry partners. + References No definition available. + Details
Name: | rckt_NumberOfTechnologyPlatformsDesignedInCollaborationWithAcademicAndIndustryPartners
Namespace Prefix: | rckt_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 + Details
Name: | us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rckt_InotekPharmaceuticalsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |